Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (GB:0R1F)
LSE:0R1F
Bristol-Myers Squibb (0R1F) Share Price & Analysis
2 Followers
0R1F Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$44.36 - $66.24
Previous Close$45.18
Volume15.91K
Average Volume (3M)180.07K
Market Cap
$90.92B
Enterprise Value$136.98B
Total Cash (Recent Filing)$9.67B
Total Debt (Recent Filing)$55.68B
Price to Earnings (P/E)-14.6
Beta0.37
Next Earnings
Jul 26, 2024EPS Estimate
$1.68Last Dividend Ex-Date
Apr 04, 2024Dividend Yield5.17%
Share Statistics
EPS (TTM)-3.10
Shares Outstanding2,027,100,096
10 Day Avg. Volume107,296
30 Day Avg. Volume180,071
Standard Deviation0.07
R-Squared0.03
Alpha0.00433
Financial Highlights & Ratios
Price to Book (P/B)-2.39
Price to Sales (P/S)10.59
Price to Cash Flow (P/CF)8.00
P/FCF Ratio7.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit3.99
Enterprise Value/Ebitda33.12
Forecast
1Y Price Target
$53.27Price Target Upside19.12% Upside
Rating ConsensusHold
Number of Analyst Covering16
Bristol-Myers Squibb News
PremiumCompany Announcements
Bristol-Myers Squibb Q1 Earnings Call Strategy Insights
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company announced a $1.5B cost savings initiative which will be reinvested to improve efficiency.
Financial PerformanceAnalyst's market perform rating suggests that shares are fairly valued with stable cash flows from I/O and hematology businesses.
Product PerformanceReblozyl sales may exceed expectations with strong prescription growth, indicating robust demand.
Bears Say
Financial PerformanceTougher quarter for Bristol with low-quality earnings driven by legacy business, coupled with a reduced target price due to updated growth asset expectations.
Product PerformanceKey growth products like Camzyos, Sotyktu, and Abecma underperformed, indicating challenges in Bristol's growth portfolio.
Strategic ConcernsRecent mergers and acquisitions are considered dilutive in the near term, raising concerns about the short-term financial impact on the company.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.30% Insiders
24.13% Mutual Funds
24.89% Other Institutional Investors
50.68% Public Companies and
Individual Investors
0R1F FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest share price was $44.35 and its highest was $66.24 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Jul 26, 2024 which is in 87 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Apr 25, 2024. The company reported -$4.4 earnings per share for the quarter, beating the consensus estimate of -$4.412 by $0.012.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 5.17%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is $1.68.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,027,100,100 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of -$4.4 in its last earnings report, beating expectations of -$4.412. Following the earnings report the stock price went down -8.774%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$53.27 (19.12% Upside)
$53.27 (19.12% Upside)
Blogger Sentiment
Bullish
GB:0R1F Sentiment 92%
Sector Average 71%
Sector Average 71%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.27%
12-Months-Change
Fundamentals
Return on Equity
-25.45%
Trailing 12-Months
Asset Growth
5.04%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
0R1F Company Deck
---
0R1F Earnings Call
Q1 2024
0:00 / 0:00
---
0R1F Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
0R1F Stock 12 Months Forecast
Average Price Target
$53.27
▲(19.12% Upside)
Technical Analysis
Best Analysts Covering 0R1F
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+17.76%
reiterated a sell rating 22 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +17.76% per trade.
---